Preferred Label : Mupadolimab;
NCIt synonyms : Anti-CD73 Monoclonal Antibody CPI-006;
NCIt definition : A type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme
5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase;
NT5E), with potential immunomodulating and antineoplastic activities. Upon intravenous
administration, mupadolimab targets and binds to CD73 on tumor cells, leading to internalization
of CD73. This prevents CD73-mediated conversion of extracellular adenosine monophosphate
(AMP) to adenosine, thereby preventing adenosine-mediated suppression of lymphocyte
activity and increasing the activity of cytotoxic T-lymphocytes (CTLs). This also
activates macrophages, and reduces the activity of both myeloid-derived suppressor
cells (MDSCs) and regulatory T-lymphocytes. By abrogating the inhibitory effect on
the immune system and enhancing the CTL-mediated immune response against cancer cells,
tumor cell growth is decreased. CD73, a plasma membrane protein belonging to the 5'-nucleotidase
(NTase) family, is upregulated on a number of cancer cell types and catalyzes the
conversion of extracellular nucleotides, such as AMP, to membrane-permeable nucleosides,
such as adenosine; it plays a key role in adenosine-mediated immunosuppression within
the tumor microenvironment.;
UNII : 23ET6940RM;
CAS number : 2451856-97-4;
Molecule name : CPI 006; CPI-006; CPX-006;
NCI Metathesaurus CUI : CL562920;
Origin ID : C156061;
UMLS CUI : C5554551;
Currated CISMeF NLP mapping
- CPI-006 [MeSH Supplementary Concept]
- Semantic type(s)
- UMLS correspondences (same concept)
- CPI-006 [MeSH Supplementary Concept]
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
